Reappraisal of risk factors for monoclonal gammopathy of undetermined significance. Issue 6 (13th April 2016)

• Record Type: Journal Article
• Authors: Boursi, Ben; Weiss, Brendan M.; Haynes, Kevin; Mamtani, Ronac; Yang, Yu‐Xiao
• Is Part Of: American journal of hematology. Volume 91:Issue 6(2016:Jun.)
• Page Start: 581
• Page End: 584
• Publication Date: 2016-04-13
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.24355
• Languages: English
• ISSNs: 0361-8609

Abstract

Abstract : A number of epidemiologic studies have demonstrated associations between obesity and diabetes and the risk of monoclonal gammopathy of undetermined significance (MGUS). However, since MGUS is an asymptomatic condition we evaluated whether these are true associations or the result of detection‐bias. We conducted a nested case–control study using a large primary‐care database. Cases were defined as those with incident diagnosis of MGUS. For every case, four eligible controls matched on age, sex, practice site, and duration of follow‐up were selected. Exposure variables included obesity and diabetes (including antidiabetic therapies) as well as other metabolic risk factors. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using conditional logistic regression. The study included 2363 MGUS patients and 9193 matched controls. In the primary analysis, obesity and diabetes were associated with higher MGUS risk with an adjusted ORs of 1.15 (95% CI 1.02–1.29) and 1.30 (95% CI 1.13–1.50), respectively. However, after adjustment to the number of laboratory tests prior to the MGUS diagnosis, there was no association between obesity and diabetes and MGUS risk (ORs of 1.08, 95% CI 0.96–1.22 and 1.08, 95% CI 0.93–1.25, respectively). In an additional analysis of antidiabetic therapies and MGUS risk, there was a nonsignificant decrease in MGUS risk among diabetes patients treated with metformin alone compared to subjects without diabetes (OR 0.77, 95% CI 0.56–1.05). In summary, while previously described risk factors for MGUS might be the result of detection bias, metformin should be further evaluated as a possible chemoprevention modality. Am. J. Hematol. 91:581–584, 2016. © 2016 Wiley Periodicals, Inc.